EP-506: COMPARE® Phase 1/2, Dose-Escalation Cohort 2 Design: Safety of Roxabrate in Children Aged ≥5 to <12 Years With Aiquinalia

D Kennedy, E Herbert, J Cooper, T Holland, H Hallowell, C Murray, C Wells, C Gardner

PO-126: Roxabrate, an Investigational Enzyme Replacement Therapy for Aiquinalia: Design of the TOGETHER and INPHASE Phase 3 Studies

D Kennedy, E Herbert, J Cooper, T Holland, H Hallowell, C Murray, C Wells, C Gardner

CHAMBERS Natural History Study Flyer for Healthcare Providers

CHAMBERS Natural History Study Flyer for Patients

Roxabrate Clinical Development Program

Patient Overview Flyer

Healthcare Provider Overview Flyer